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An artificial receptor for proMMP-9 was created by fusing tissue inhibitor of
MMP-1 (TIMP-1) with type II transmembrane mosaic serine protease (MSP-T1).
Expression of MSP-T1 in 293T cells induced binding of proMMP-9, which was pro-
cessed by MMP-2 activated by membrane type 1 MMP (MT1-MMP). HT1080 cells
transfected with the MSP-T1 gene produced activated MMP-9 in collagen gel,
and addition of proMMP-2 to the culture augmented it, which resulted in inten-
sive collagen digestion. These cells metastasized into chick embryonic liver more
than control cells. Treatment of HT1080 cells with concanavalin A in the presence
of exogenous proMMP-2 induced activation of not only proMMP-2 but also
proMMP-9. Knockdown of MT1-MMP or TIMP-2 expression with siRNA sup-
pressed activation of both proMMP-2 and proMMP-9. Transfection of TIMP-1
siRNA suppressed cell binding and activation of proMMP-9, but not proMMP-2
activation. Knockdown of a disintegrin and metalloproteinase 10 (ADAM10)
expression reduced cell binding and processing of proMMP-9. These results sug-
gest that proMMP-9, which binds to a receptor complex containing TIMP-1 and
ADAM10, is activated by the MT1-MMP/MMP-2 axis, and MMP-9 thus activated
stimulates cellular proteolysis and metastasis.
M atrix metalloproteinase-2 and MMP-9 are type IV colla-genase/gelatinase, and their expression is often associ-
ated with tumor aggressiveness and a poor prognosis
(reviewed in Ref. 1,2). Membrane type 1 MMP was first iden-
tified as an activator of latent MMP-2 (proMMP-2).(3) In addi-
tion to proMMP-2, a variety of substrates of MT1-MMP were
identified, including ECM proteins, cell adhesion molecules,
cytokines, and others.(4–7) ProMMP-2 is activated in a variety
of tumor tissues in which MT1-MMP is overexpressed. In con-
trast, proMMP-9 activation was detected in limited numbers of
tumor samples, such as non-small-cell lung carcinoma and
colon carcinomas,(8–10) and the active form of MMP-9 was
predominantly present in colon carcinoma patients with metas-
tases.(8) ProMMP-9 can be processed in vitro by various pro-
teases including MMP-2, MMP-3, and serine proteases,
however, the molecular mechanism of proMMP-9 activation
in vivo still remains to be solved.(1)
In proMMP-2 activation mechanism, the MT1-MMP/TIMP-
2 complex serves as a receptor for proMMP-2, which is then
processed by adjacent TIMP-2-free MT1-MMP.(11–14) To
mimic this model, TIMP-2 was fused with type II transmem-
brane MSP to create MSP-T2 as an artificial receptor for
proMMP-2.(15) It was reported that MSP-T2 served as a recep-
tor for proMMP-2, and accelerated proMMP-2 activation by
MT1-MMP.(15) ProMMP-9 is known to bind to TIMP-1 in a
similar manner as proMMP-2 binds to TIMP-2; this suggested
model implicates TIMP-1 as a bridging molecule to tether
proMMP-9 on the cell surface for its processing.(1,2)
In the present study, a TIMP-1 chimera protein with MSP,
MSP-T1, was constructed, which served as an artificial recep-
tor for proMMP-9 and induced proMMP-9 activation by the
MT1-MMP/MMP-2 axis. Stable expression of MSP-T1 in
HT1080 fibrosarcoma cells stimulated proMMP-9 activation
and metastasis. ProMMP-9 processing through TIMP-1-con-
taining receptor and the MT1-MMP/MMP-2 axis was shown
in ConA-treated HT1080 cells.
Materials and Methods
Cell culture. Human embryonic kidney 293T and fibrosar-
coma HT1080 cells were obtained from ATCC (Manassas,
VA, USA) and cultured in DMEM (Sigma, St. Louis, MO,
USA) supplemented with 5% FCS. HT1080 cells stably
expressing MSP-T1 were generated by transfecting MSP-T1
plasmid, and transfected cells were selected under 5 lg/mL
puromycin (Sigma). Type I collagen Cellmatrix Type I(P) was
purchased from Nitta Gelatin (Osaka, Japan). Recombinant
TIMP-1 and TIMP-2 proteins were gifts from the Daiichi Fine
Chemical Co. (Takaoka, Japan). A synthetic MMP inhibitor
BB94 (batimastat) was a kind gift from the Kotobuki Pharma-
ceutical Co. (Nagano, Japan).
Antibodies. Monoclonal antibodies against MMP-9
(56-2A4), MT1-MMP (222-2D12), TIMP-1 (7-6C1), and
TIMP-2 (67-4H11) were gifts from the Daiichi Fine Chemical
Co. An antibody against ADAM10 was purchased from R&D
Systems (Minneapolis, MN, USA).
Plasmids. Expression plasmids for MT1-MMP, MSP-T1,
MMP-2, and MMP-9 were constructed in pEAK8 vector (Edge
BioSystems, Gaithersburg, MD, USA) as described previ-
ously.(16–19) The fusion gene for MSP-T1, which encodes
amino acid residues 1–188 of MSP and 24–207 of TIMP-1,
was constructed by replacing the fragment encoding TIMP-2
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of MSP-T2 with that of TIMP-1.(15) The human TIMP-1
cDNA fragment encoding amino acid residues 24–207 was
amplified by PCR using 50 and 30 primers with extra EcoRI
and XbaI sites, respectively (GAATTCTGCACC
TGTGTCCCA CCCCAC and TCTAGATCAGGCTA
TCTGGGACCGCAG; restriction enzyme site). The cDNA
encoding mutant MMP-9 lacking C-terminal hinge and hemo-
pexin-like domains (DMMP-9) was amplified by PCR using a
primer TCTAGATCA ACCATAGAGGTGCCGGATGCC (re-
striction site). The cDNA encoding MMP-9 mutants with
amino acid substitution at Met41 and Phe88 with Val was
amplified by PCR using mutation primers CTCGGGTGGCA-
GAGGTGCGTGGAGAGTCGA and CAGA CCTGGGCA-
GAGTCC AAACCTTTGAGG (mutated nucleotide),
respectively.
RNA interference. RNA interference technology was used to
generate specific knockdown of MT1-MMP, TIMP-1, TIMP-2,
ADAM10, and MMP-9 mRNA transcription. Small interfering
RNA was prepared by FASMAK (Kanagawa, Japan). The
siRNA target sequences were as follows: MT1-MMP-I, CCA-
GAAGCTGAA GGTAGAA; MT1-MMP-II, GCGAT-
GAAGTCTTCACTTA; TIMP-1-I, TCAACCAG ACCACCT
TATA; TIMP-1-II, GATGTATAAAGGGTTCCAA; TIMP-2-I,
GGATCCA GTATGAGATCAA; TIMP-2-II, GAGATCAAG
CAGATAAAGA; ADAM10-I, GATA TCCAGTCATGTT
AAA; ADAM10-II, CTGGAATTATTACTGTTCA; MMP-9-I,
CAC AACAUCACCUAUUGGA; MMP-9-II, GGAGUACUC
GACCUGUACC. Scrambled oligo was used as a negative con-
trol. Small interfering RNA reverse transfection was carried
out using Lipofectamine RNAiMAX (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s instructions.
Zymography. ProMMP-2, proMMP-9, and proMMP-9
mutant supernatants were prepared from 293T cells trans-
fected with the respective expression plasmids, as previously
described.(21) 293T cells cultured in a 24-well microplate
were transfected with expression plasmids, cultured in
DMEM supplemented with 5% FCS for 24 h, and incubated
in 300 lL Opti-MEM (Invitrogen) containing proMMP-2 and
proMMP-9. Both MMP-2 and MMP-9 in the supernatant
were examined by mixing with a same volume of zymogra-
phy sample buffer. For the detection of cell-bound MMP-2
and MMP-9, cells were washed twice with PBS, and then
dissolved in 200 lL sample buffer by sonication. These
samples were incubated at 37°C for 20 min, and subjected
to gelatin zymography gel containing gelatin labeled with
Alexa Fluor 680 (Molecular Probes, Eugene, OR, USA).
Gels were processed and monitored by a LI-COR Bio-
sciences Odyssey IR imaging system (Lincoln, NE, USA) as
described previously.(15)
Western blot analysis. Cell lysates or proteins precipitated
from conditioned medium with 10% trichloroacetic acid were
analyzed by Western blotting with the indicated antibody. Goat
anti-mouse antibody conjugated with Alexa Fluor 680 was
used as a secondary antibody. The signal was monitored using
a LI-COR Odyssey IR imaging system. Precision Plus Protein
Standards were used as molecular weight standards (Bio-Rad,
Hercules, CA, USA).
Chick embryo assay. The assay was done as originally
described by Endo et al.(17) Briefly, HT1080 cells stably trans-
fected with pEAK control plasmid or MSP-T1 expression plas-
mid (1.0 9 105 cells per egg) were injected into the
chorioallantoic membrane vein of chicken eggs 11 days after
fertilization, and incubated for a further 7 days. Ten eggs were
used for the injection of each type of cell. The number of
HT1080 cells that colonized liver was estimated by quantita-
tive real-time PCR as described previously.(15,17)
Gelatin degradation. Alexa Fluor 680-labeled gelatin
(150 ng/200 lL Opti-MEM) was incubated with HT1080 cells
in a 24-well microplate for 1 h, separated on 10% SDS-PAGE,
and detected by a LI-COR Odyssey IR imaging system.(15)
Results
MSP-T1 functions as a receptor for proMMP-9. 293T cells
transfected with MSP-T1 and/or MT1-MMP plasmids were
incubated with proMMP-2 and proMMP-9, and cell-bound
MMP-2 and MMP-9 were examined by gelatin zymography.
ProMMP-9 bound to the cells expressing MSP-T1 more effec-
tively than to control cells (Fig. 1a, Cells). Expression of
MT1-MMP alone induced activation of proMMP-2, but not
proMMP-9. Coexpression of MSP-T1 with MT1-MMP induced
activation of both proMMP-2 and proMMP-9. To confirm that
proMMP-9 activation is mediated by transfected cells, trans-
fected cells were incubated with proMMP-2, and then super-
natants from transfected cells were incubated with proMMP-9
(Fig. 1a, Sup). ProMMP-9 was not processed in the super-
natant from cells expressing MSP-T1, MT1-MMP, and MMP-
2. Next, to examine the requirement of MMP-2 in proMMP-9
activation through MSP-T1/MT1-MMP, cells coexpressing
MSP-T1 and MT1-MMP were incubated with proMMP-9 and
2-fold serially diluted proMMP-2 (Fig. 1b). ProMMP-9 activa-
tion was shown to depend on MMP-2 concentration added to
the culture. The time course experiment indicated that
proMMP-9 activation by the cells expressing MSP-T1/MT1-
MMP/MMP-2 was induced at 0.2 h and reached a plateau at
1–2 h after incubation (Fig. 1c). ProMMP-9 binds to TIMP-1
through the carboxy-terminal hemopexin-like domain.
ProMMP-9 mutant lacking hemopexin-like domain (DMMP-9)
was compared with wild-type proMMP-9 for binding and pro-
cessing by cells expressing MSP-T1 and MT1-MMP in the
presence of proMMP-2 (Fig. 1d). Wild-type proMMP-9 bound
to the cells expressing MSP-T1 and was activated by the cells
expressing MSP-T1 and MT1-MMP in the presence of
proMMP-2. However, DproMMP-9 failed to bind to MSP-T1-
expressing cells and was not activated by the cells expressing
MSP-T1 and MT1-MMP. ProMMP-9 was shown to be cleaved
in vitro by activated MMP-2 at the Glu40–Met41 amide bond
to generate an activation intermediate form, which is converted
to the fully active form through the autocleavage at the Arg87–
Phe88 amide bond.(22) To confirm proMMP-9 cleavage sites by
the cells expressing MSP-T1 and MT1-MMP in the presence
of proMMP-2, wild-type or mutant proMMP-9 with the amino
acid substitution at Met41 (Fig. 1e, Mut1) or Phe88 (Fig. 1e,
Mut2) was incubated with the cells expressing MSP-T1 and
MT1-MMP in the presence of proMMP-2. Wild-type
proMMP-9 was converted to fully active form by these cells,
but proMMP-9 mutant with amino acid substitution at Met41
(Mut1) was not processed. ProMMP-9 mutant with an amino
acid substitution at Phe88 (Mut2) was cleaved to generate an
activation intermediate form. These results indicate that
proMMP-9 is processed by the cells expressing MSP-T1,
MT1-MMP in the presence of proMMP-2 through the cleavage
at the same sites as in vitro activation by active MMP-2. The
activation efficiency by these cells was dramatically improved
compared with activation by MMP-2 in vitro.(22)
Expression of MSP-T1 in HT1080 cells. HT1080 cells were sta-
bly transfected with MSP-T1 plasmid, and cultured in collagen
gel in the presence or absence of exogenously added proMMP-
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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2 to examine proMMP-9 activation and degradation of colla-
gen gel (Fig. 2). HT1080 cells migrated out of the collagen
gel, but collagen degradation was not obvious in the culture of
cells without exogenous proMMP-2. In the presence of exoge-
nously added proMMP-2, collagen gel was degraded inten-
sively by the cells expressing MSP-T1, and moderately by
control cells (Fig. 2b). Gelatin zymography analysis showed
that endogenous proMMP-2 was activated equally by the cells
transfected with control or MSP-T1 plasmid, but proMMP-9
processing was detected only in the cells expressing MSP-T1
in the absence of exogenously added proMMP-2. Addition of
proMMP-2 to the culture produced a large amount of active
MMP-2, which resulted in significant proMMP-9 processing in
control cells and a more dramatic effect in MSP-T1-expressing
cells (Fig. 2c). The metastatic ability of HT1080 cells express-
ing MSP-T1 was analyzed by the chick embryo system.
HT1080 cells expressing MSP-T1 metastasized into liver
4-fold more efficiently than control cells (Fig. 2d).
Fig. 1. ProMMP-9 activation by cells expressing artificial receptor for proMMP-9 (MSP-T1), membrane type 1 (MT1)-MMP, and MMP-2. (a) Con-
trol plasmid or expression plasmid for MT1-MMP (200 ng) and/or MSP-T1 (300 ng) was transfected into 293T cells in a 24-well microplate.
Twenty-four hours after transfection, cells were incubated in Opti-MEM containing proMMP-2 (100 nM) and proMMP-9 (20 nM) for 2 h. Cell-
bound MMP-2 and MMP-9 were analyzed by gelatin zymography (Cells). Cells were incubated with proMMP-2 for 2 h, and then the supernatant
was incubated with proMMP-9 (20 nM) for a further 2 h. ProMMP-9 processing was monitored by zymography (Sup). Expression of MSP-T1 and
MT1-MMP was detected by Western blotting using anti-tissue inhibitor of MMP-1 and anti-MT1-MMP antibodies, respectively (lower panels). (b)
293T cells transfected with expression plasmids for MSP-T1 and MT1-MMP as described above were incubated with proMMP-9 (20 nM) and seri-
ally diluted proMMP-2 for 2 h, and then cell-bound MMP-2 and MMP-9 were subjected to gelatin zymography. Gels were processed and moni-
tored by an infrared imaging system with low (top) and high sensitivity (bottom). (c) 293T cells transfected as above were incubated with
proMMP-2 (100 nM) for 1 h, and then proMMP-9 (20 nM) was added and incubated for the indicated period. Cell-bound MMP-2 and MMP-9
were detected as above. (d) 293T cells transfected with control, MSP-T1 and/or MT1-MMP plasmid as described above were incubated with
proMMP-2 and wild-type proMMP-9 or proMMP-9 mutant lacking hemopexin-like domain (DMMP-9) for 2 h, and cell-bound (Cell) or super-
natant (Sup) MMP-2 and MMP-9 were detected by gelatin zymography. (e) MT1-MMP plasmid (1 lg) was cotransfected with control or MSP-T1
plasmid (1 lg) into 293T cells cultured in a 35-mm dish. Twenty-four hours after incubation, 50 nM wild-type or mutant proMMP-9 with an
amino acid substitution at Met41 (Mut1) or Phe88 (Mut2) was incubated with cells in the presence of proMMP-2 (50 nM) for 3 h. Supernatant
was concentrated with trichloroacetic acid, and subjected to Western blotting using an antibody against MMP-9. Expression of MSP-T1 and MT1-
MMP was detected by Western blotting as described above (lower panels).
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Activation of proMMP-9 by HT1080 cells. HT1080 cells cul-
tured in collagen gel in the presence of exogenous proMMP-2
activated proMMP-2 and slightly activated proMMP-9. To
induce more efficient proMMP-2 activation in HT1080 cells,
cells were treated with 2-fold serially diluted ConA in the
presence of exogenous proMMP-2 (Fig. 3a). ProMMP-2 acti-
vation was induced even at low ConA concentration. Treat-
ment with ConA induced cell binding and processing of
proMMP-9 in HT1080 cells, but they required higher ConA
concentration than proMMP-2 activation.
As shown in Figure 1, activation of proMMP-9 by cells
expressing MSP-T1 and MT1-MMP required a considerable
concentration of proMMP-2. Thus, requirement of MMP-2 in
proMMP-9 activation by ConA-treated HT1080 cells was
examined (Fig. 3b). Addition of exogenous proMMP-2 to
ConA-treated HT1080 cells induced activation of proMMP-2
and proMMP-9, depending on the proMMP-2 concentration.
The time course experiment showed that proMMP-9 was pro-
cessed to the intermediate activation form in 1 h and to fully
active form in 2–3 h (Fig. 3c).
The effect of MMP inhibitors on proMMP-9 activation by
ConA-treated HT1080 cells was examined (Fig. 3d). Addition
of TIMP-2 or BB94 interfered with activation of both
proMMP-2 and proMMP-9 by ConA-treated HT1080 cells.
Cells treated with TIMP-1 processed proMMP-2 to the inter-
mediate activation form, and failed to activate proMMP-9.
These results suggest that proMMP-2 activation by MT1-MMP
is associated with proMMP-9 processing in ConA-treated
HT1080 cells.
Analysis of proMMP-9 activation mechanism by siRNA. To
confirm the association of MT1-MMP with proMMP-9
processing, MT1-MMP siRNA was transfected into HT1080
cells, and proMMP-9 activation was examined (Fig. 4).
Knockdown of MT1-MMP expression suppressed activation of
not only proMMP-2 but also proMMP-9 (left panel). MSP-
TIMP-1 was shown to act as a receptor for pro-MMP-9, which
facilitated proMMP-9 activation by the MT1-MMP/MMP-2
axis. This suggested a possibility that TIMP-1 acts as a part of
the proMMP-9 receptor and induces its processing in
ConA-treated HT1080 cells. To test it, TIMP-1 expression was
downregulated by the transfection of siRNA, and proMMP-9
activation was examined. Knockdown of TIMP-1 did not alter
proMMP-2 activation, but suppressed binding of proMMP-9 to
the cells and subsequent activation in ConA-treated HT1080
cells (middle panel). Knockdown of TIMP-2 did not alter
proMMP-9 binding but interfered with activation of both
proMMP-2 and proMMP-9. These results suggest that TIMP-1
serves as a part of the proMMP-9 receptor, which induces sub-
sequent proMMP-9 processing. Expressed at a considerable
level in HT1080 cells, ADAM10 is known to be inactivated
by TIMP-1.(23) Transfection of ADAM10 siRNA did not affect
proMMP-2 activation, but suppressed cell binding and process-
ing of proMMP-9 (right panel).
Contribution of MMP-9 to gelatin degradation by HT1080 cells.
In order to examine the contribution of MMP-2 and MMP-9 to
ECM degradation by HT1080 cells, MMP-9 expression was
knocked down through siRNA transfection, and gelatin degra-
dation by these cells was monitored (Fig. 5). Gelatin was not
significantly degraded by ConA-treated HT1080 cells in the
absence of exogenous proMMP-2. Addition of proMMP-2 to
ConA-treated cells generated active MMP-2 and MMP-9,
which resulted in intensive gelatin degradation. Knockdown of
Fig. 2. Stable transfection of artificial receptor for
proMMP-9 (MSP-T1) into HT1080 cells. (a) HT1080
cells stably transfected with control or MSP-T1
plasmid were subjected to Western blotting using
an antibody against tissue inhibitor of MMP-1. (b)
HT1080 cells transfected with control or MSP-T1
plasmid (2 9 105 cells) were suspended in 100 lL
collagen mixture. A 20-lL drop of collagen mixture
containing cells was polymerized on the bottom of
a 24-well microplate, cultured in DMEM
supplemented with 5% FCS for a day, and then in
Opti-MEM with or without 50 nM proMMP-2 for
2 days. Cells in collagen culture were photographed
under a phase contrast microscope. (c) Cells
cultured in collagen gel as described above were
dissolved in a sample buffer, and subjected to
gelatin zymography. (d) HT1080 cells transfected
with control or MSP-T1 plasmid were injected into
the chorioallantoic membrane vein of chicken eggs,
and cells that metastasized into liver were
analyzed. *P < 0.05.
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MMP-9 expression in these cells considerably reduced gelatin
degradation by ConA-treated cells. These results indicate that
not only MMP-2 but also MMP-9 activated by HT1080 cells
contributes to gelatin degradation.
Discussion
Activation of proMMP-2 by MT1-MMP is a feature of the
malignant phenotype of various tumors.(4–7) Tumor-specific
proMMP-9 activation is restricted to a limited numbers of tis-
sues, and the molecular mechanism of proMMP-9 activation
in vivo still remains unsolved.(8–10) ProMMP-2 and proMMP-9
bind to TIMP-2 and TIMP-1 through the carboxy-terminal
domain of each molecule, respectively.(1,2) Formation of a
trimolecular complex consisting of proMMP-2/TIMP-2/MT1-
MMP is the initial step for proMMP-2 activation by
MT1-MMP.(11–13) Previously, MSP-T2 was constructed as an
artificial receptor for proMMP-2, which accelerated proMMP-2
activation by MT1-MMP.(15) Assuming a similar scenario in
proMMP-9 activation process, in which binding of proMMP-9
to the receptor containing TIMP-1 is the initial step for activa-
tion, MSP-T1 was created as an artificial receptor for
proMMP-9. Indeed, MSP-T1 served as a receptor for
proMMP-9, which was effectively processed by the MT1-
MMP/MMP-2 axis (Fig. 1). Membrane-bound serine proteases,
such as MSP and matriptase, were negative as a cell-surface
proMMP-9 activator, when coexpressed with MSP-T1 (data
not shown). Toth et al.(24) reported activation of proMMP-9 by
membrane fraction from cells expressing MMP-2 and MT1-
MMP, however, incubation of proMMP-9 with these cells
failed to activate proMMP-9, which was consistent with the
present study. Coexpression of MSP-T1 with MT1-MMP
induced dramatic proMMP-9 activation in the presence of
proMMP-2. ProMMP-9 is activated by these cells through the
cleavage at the site identical with those by active MMP-2
in vitro.(22) These results suggest a proMMP-9 activation pro-
cess in which proMMP-9 is anchored to the cell surface
through a TIMP-1-containing receptor and is subsequently pro-
cessed by MMP-2 activated and anchored on the cell surface
by MT1-MMP. HT1080 cells in collagen gel did not show
detectable proMMP-9 processing, but addition of proMMP-2
induced significant proMMP-9 processing. Treatment of
HT1080 cells with ConA caused more efficient proMMP-2
activation than collagen culture, and induced cell binding and
Fig. 3. Induction of proMMP-2 and proMMP-9 activation in HT1080 cells. (a) HT1080 cells were cultured in DMEM supplemented with 5% FCS
for 24 h, and then in Opti-MEM containing proMMP-2 (50 nM) and serially diluted concanavalin (ConA) for 12 h. Cell-bound MMP-2 and MMP-9
were analyzed by gelatin zymography. (b) HT1080 cells cultured as above were incubated in Opti-MEM containing ConA (50 lg/mL) and serially
diluted proMMP2 for 12 h, and cell-bound MMP-2 and MMP-9 were analyzed by gelatin zymography. (c) HT1080 cells cultured as above were
incubated in Opti-MEM containing ConA (50 lg/mL) and proMMP-2 (50 nM) for the indicated period, and cell-bound MMP-2 and MMP-9 were
analyzed by gelatin zymography. (d) HT1080 cells cultured as above were incubated in Opti-MEM containing ConA (50 ng/mL) and proMMP-2
(50 nM) with mock (), tissue inhibitor of tissue inhibitor of metalloproteinase (TIMP)-1 (10 lg/mL), TIMP-2 (10 lg/mL), or BB94 (1 lM) for 12 h.
Cell-bound and supernatant MMP-2 and MMP-9 were analyzed by gelatin zymography.
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processing of proMMP-9 in the presence of exogenously added
proMMP-2 (Fig. 3). Knockdown of MT1-MMP or TIMP-2
expression, which is essential for proMMP-2 activation, sup-
pressed processing of not only proMMP-2 but also proMMP-9.
Knockdown of TIMP-1 expression downregulated cell binding
and processing of proMMP-9, but did not affect proMMP-2
activation. These results indicate that TIMP-1 is involved in
cell-binding of proMMP-9, which is subsequently processed by
MMP-2 activated by MT1-MMP. ADAM10 is known to be
inactivated by TIMP-1, suggesting the possibility that
ADAM10 acts as a cell-surface binding molecule of TIMP-
1.(23) Knockdown of ADAM10 expression by siRNA reduced
both binding and processing of proMMP-9. These results may
suggest that ADAM10 is one of the receptors for TIMP-1 and
that the ADAM10/TIMP-1 complex acts as a receptor for
proMMP-9, which is subsequently processed by the MT1-
MMP/MMP-2 axis. However, reconstitution of proMMP-9
receptor by coexpressing ADAM10 and TIMP-1 was not suc-
cessful (data not shown). Actually, ADAM10 and TIMP-1 pro-
tein expression was not significantly affected by ConA
treatment of HT1080 cells (data not shown). The cell surface
event induced by ConA treatment seems to be complicated,
and the mechanism by which ADAM10 participates in
proMMP-9 processing still remains unsolved. Several TIMP-1
binding molecules such as CD44, CD63, and integrins were
reported, which may function as proMMP-9 receptors by form-
ing complexes with TIMP-1.(23) Association of CD44 and
MT1-MMP with proMMP-9 activation in osteoclasts and for-
mation of the proMMP-9/CD44/TIMP-1 complex were
reported, although the molecular mechanism and physiological
significance of them in relation to proMMP-9 processing still
remain to be solved.(20,25)
Fig. 4. Suppression of proMMP-9 processing by
siRNA. HT1080 cells transfected with control RNA or
siRNA for membrane type 1 (MT1)-MMP (MT1-
MMP-I, MT1-MMP-II), tissue inhibitor of tissue
inhibitor of metalloproteinase (TIMP)-1 (TIMP-1-I,
TIMP-1-II), TIMP-2 (TIMP-2-I, TIMP-2-II), or a
disintegrin and metalloproteinase 10 (ADAM10)
(ADAM10-I, ADAM10-II) were cultured in Opti-MEM
containing concanavalin A (50 ng/mL) and
proMMP-2 (50 nM) for 12 h. Cell-bound MMP-2
and MMP-9 were analyzed by gelatin zymography.
The expression of each protein was analyzed by
Western blotting.
Fig. 5. Gelatin degradation by MMP-2 and MMP-9
in HT1080 cells. HT1080 cells transfected with
control RNA or MMP-9 siRNA (MMP-9-I, MMP-9-II)
were cultured in Opti-MEM containing
concanavalin A (50 ng/mL) with or without
proMMP-2 (50 nM) for 12 h. MMP-2 and MMP-9
bound to cells were analyzed by gelatin
zymography (left panel). These cells were incubated
with fluorescence-labeled gelatin () for 1 h, and
gelatin degradation was monitored (right panel).
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
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Expression of MSP-T1 in HT1080 cells stimulated
proMMP-9 activation by the MT1-MMP/MMP-2 axis, which
in turn enhanced metastatic ability in vivo and collagen degra-
dation in vitro. These results showed for the first time that
activation of proMMP-9 stimulates tumor metastasis. Addition
of proMMP-2 to ConA-treated HT1080 cells generated active
MMP-2, which consequently processed endogenous proMMP-
9. Both MMP-2 and MMP-9 cleave various substrates, such as
ECM molecules, membrane proteins, cytokines, and growth
factors that regulate key signaling pathways in cell growth,
migration, invasion, and angiogenesis.(1,2) Membrane-bound
MMP-9 thus activated by the MT1-MMP/MMP-2 axis may
have advantage over pericellular proteolysis. Participation of
MMP-9 to coordinate action of MT1-MMP and MMP-2 further
facilitates pericellular proteolysis for tumor invasion and
metastasis. ProMMP-2 is often abundantly expressed by stro-
mal cells located adjacent to malignant epithelial cells, and
functions as a mediator of tumor–stroma interaction by being
activated by tumor-specific MT1-MMP, which may subse-
quently activate proMMP-9. In conclusion, proMMP-9, which
is anchored though a receptor complex containing TIMP-1, is
activated by the MT1-MMP/MMP-2 axis. Thus activated,
MMP-9 contributes to pericellular proteolysis for tumor inva-
sion and metastasis in collaboration with MT1-MMP and
MMP-2.
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ADAM10 a disintegrin and metalloproteinase 10
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IR infrared
MSP mosaic serine protease
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